Literature DB >> 26543432

Impact of the US Preventive Services Task Force Grade D Recommendation: Assessment of Evaluations for Elevated Prostate-specific Antigen and Prostate Biopsies in a Large Urology Group Practice Following Statement Revision.

Kathleen F McGinley, Gregory C McMahon1, Gordon A Brown.   

Abstract

On October 7, 2011, the United States Preventive Services Task Force (USPSTF) released their evidence statement and grade D recommendation against prostate-specific antigen (PSA)-based prostate cancer screening. Using a time series design, we assessed the effect of this recommendation upon evaluations for elevated PSA levels and prostate biopsies in our large urology group practice. We found that, despite a 24.1% increase in total visits, the 32 urologists in our practice completed 16.4% fewer evaluations for elevated PSA levels (317 fewer evaluations per month; P = .017) and 21.4% fewer prostate biopsies (42 fewer biopsies per month; P = .001) in the 2 years following the USPSTF grade D recommendation.

Entities:  

Keywords:  Prostate biopsies; Prostate cancer screening; Prostate-specific antigen; United States

Year:  2015        PMID: 26543432      PMCID: PMC4633661     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  18 in total

1.  Early detection of prostate cancer: AUA Guideline.

Authors:  H Ballentine Carter; Peter C Albertsen; Michael J Barry; Ruth Etzioni; Stephen J Freedland; Kirsten Lynn Greene; Lars Holmberg; Philip Kantoff; Badrinath R Konety; Mohammad Hassan Murad; David F Penson; Anthony L Zietman
Journal:  J Urol       Date:  2013-05-06       Impact factor: 7.450

2.  What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation.

Authors:  William J Catalona; Anthony V D'Amico; William F Fitzgibbons; Omofolasade Kosoko-Lasaki; Stephen W Leslie; Henry T Lynch; Judd W Moul; Marc S Rendell; Patrick C Walsh
Journal:  Ann Intern Med       Date:  2012-07-17       Impact factor: 25.391

3.  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2012-07-17       Impact factor: 25.391

4.  PSA screening: determinants of primary-care physician practice patterns.

Authors:  G E Tasian; M R Cooperberg; M B Potter; J E Cowan; K L Greene; P R Carroll; J M Chan
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-11-29       Impact factor: 5.554

5.  Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices.

Authors:  Tomy Y Perez; Matthew R Danzig; Rashed A Ghandour; Ketan K Badani; Mitchell C Benson; James M McKiernan
Journal:  Urology       Date:  2014-11-11       Impact factor: 2.649

6.  National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.

Authors:  Michael W Drazer; Dezheng Huo; Scott E Eggener
Journal:  J Clin Oncol       Date:  2015-06-08       Impact factor: 44.544

7.  Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates.

Authors:  Bimal Bhindi; Muhammad Mamdani; Girish S Kulkarni; Antonio Finelli; Robert J Hamilton; John Trachtenberg; Alexandre R Zlotta; Andrew Evans; Theodorus H van der Kwast; Ants Toi; Neil E Fleshner
Journal:  J Urol       Date:  2014-12-03       Impact factor: 7.450

8.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

9.  Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation.

Authors:  Joshua A Cohn; Chihsiung E Wang; Justin C Lakeman; Jonathan C Silverstein; Charles B Brendler; Kristian R Novakovic; Michael S McGuire; Brian T Helfand
Journal:  Urol Oncol       Date:  2013-08-02       Impact factor: 3.498

10.  The impact of recent screening recommendations on prostate cancer screening in a large health care system.

Authors:  Afshin Aslani; Brian J Minnillo; Ben Johnson; Edward E Cherullo; Lee E Ponsky; Robert Abouassaly
Journal:  J Urol       Date:  2013-12-14       Impact factor: 7.450

View more
  13 in total

Review 1.  The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.

Authors:  Katherine Fleshner; Sigrid V Carlsson; Monique J Roobol
Journal:  Nat Rev Urol       Date:  2016-12-20       Impact factor: 14.432

2.  Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?

Authors:  Izak Faiena; Stuart Holden; Mathew R Cooperberg; Stuart Holden; Howard R Soule; Jonathan W Simons; Todd M Morgan; David F Penson; Alicia K Morgans; Maha Hussain
Journal:  J Clin Oncol       Date:  2018-02-05       Impact factor: 44.544

3.  Histologic Changes in Prostate Cancer Detected Subsequent to the 2012 United States Preventive Services Task Force (USPSTF) Prostate Cancer Screening Recommendation.

Authors:  Carl A Olsson; Hugh J Lavery; Kamlesh K Yadav; Ann E Anderson; Deepak Kapoor
Journal:  Rev Urol       Date:  2018

4.  Prostate biopsy characteristics: A comparison between pre- and post- United States Preventive Service Task Force Prostate Cancer Screening Guidelines of 2012.

Authors:  Navin Shah; Thomas Huebner; Vladimir Ioffe; Richard Hum
Journal:  Rev Urol       Date:  2017

5.  Diagnostic Value of Guided Biopsies: Fusion and Cognitive-registration Magnetic Resonance Imaging Versus Conventional Ultrasound Biopsy of the Prostate.

Authors:  Daniel T Oberlin; David D Casalino; Frank H Miller; Richard S Matulewicz; Kent T Perry; Robert B Nadler; Shilajit Kundu; William J Catalona; Joshua J Meeks
Journal:  Urology       Date:  2016-03-07       Impact factor: 2.649

6.  Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations.

Authors:  Isaac E Kim; Daniel D Kim; Sinae Kim; Shuangge Ma; Thomas L Jang; Eric A Singer; Saum Ghodoussipour; Isaac Yi Kim
Journal:  BMC Urol       Date:  2022-06-25       Impact factor: 2.090

7.  Prostate Biopsy Characteristics: A Comparison Between the Pre- and Post-2012 United States Preventive Services Task Force (USPSTF) Prostate Cancer Screening Guidelines.

Authors:  Navin Shah; Vladimir Ioffe; Thomas Huebner; Ivelina Hristova
Journal:  Rev Urol       Date:  2018

8.  Changes in prostate cancer detection rate of MRI-TRUS fusion vs systematic biopsy over time: evidence of a learning curve.

Authors:  B Calio; A Sidana; D Sugano; S Gaur; A Jain; M Maruf; S Xu; P Yan; J Kruecker; M Merino; P Choyke; B Turkbey; B Wood; P Pinto
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-08-01       Impact factor: 5.554

9.  Changes in Prostate Cancer Presentation Following the 2012 USPSTF Screening Statement: Observational Study in a Multispecialty Group Practice.

Authors:  Joseph Presti; Stacey Alexeeff; Brandon Horton; Stephanie Prausnitz; Andrew L Avins
Journal:  J Gen Intern Med       Date:  2019-12-09       Impact factor: 5.128

10.  US Preventive Services Task Force prostate-specific antigen screening guidelines result in higher Gleason score diagnoses.

Authors:  Glen Gejerman; Patrick Ciccone; Martin Goldstein; Vincent Lanteri; Burton Schlecker; John Sanzone; Michael Esposito; Sergey Rome; Michael Ciccone; Eric Margolis; Robert Simon; Yijun Guo; Sri-Ram Pentakota; Hossein Sadeghi-Nejad
Journal:  Investig Clin Urol       Date:  2017-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.